Leksum Partners with Medical University of Vienna to Advance LK-ICU Toward First-in-Human Trials

Leksum's agreement with the Medical University of Vienna marks a critical step toward clinical trials for LK-ICU, a therapy that could prevent diaphragm weakness in ventilated patients and reduce the burden of prolonged ICU stays.

Chicago Metrowire Staff
••Healthcare
Leksum Partners with Medical University of Vienna to Advance LK-ICU Toward First-in-Human Trials

Leksum LLC, an early-stage life sciences company based in Boston, Massachusetts, has signed an agreement with the Department of Anesthesia, Intensive Care Medicine and Pain Medicine at the Medical University of Vienna to conduct preparatory work for Phase I/II first-in-human clinical trials of its lead candidate, LK-ICU. The agreement, co-signed by Phoenestra GmbH, positions the company to move its preclinical findings into a clinical setting, where the therapy could address a significant and costly complication of critical care.

LK-ICU consists of extracellular vesicles derived from bone marrow mesenchymal stromal cells. In preclinical studies, the therapy demonstrated an almost complete preservation of diaphragm muscle fiber size and function that is normally lost during mechanical ventilation. This is important because prolonged mechanical ventilation often leads to ICU-acquired weakness, a condition that can extend weaning times and impair recovery. Extended weaning is estimated to affect the quality of life of hundreds of thousands of patients annually in the United States and Europe, underscoring the unmet need for therapies that protect muscle function during critical illness.

The agreement covers the preparatory work leading up to the trials, which Leksum plans to initiate upon closing its Series A financing round. The planning phase is expected to last several months. By conducting the early clinical work in Europe, Leksum intends to generate European clinical data that can support its regulatory path in the United States, a strategy that could accelerate development and reduce overall costs. For a small company, leveraging international clinical infrastructure and data is a pragmatic way to advance a novel biologic therapy while managing resources.

Leksum's pipeline extends beyond LK-ICU. The company is also developing therapies for skeletal muscle conditions including sarcopenia, cancer cachexia, and muscle loss associated with the use of weight-loss drugs such as GLP-1s. This broader focus suggests that the underlying technology—using extracellular vesicles to protect or restore muscle tissue—could have applications across a range of acquired muscle myopathies. If successful, LK-ICU could become a first-in-class treatment for ICU-acquired weakness, while the platform could yield additional therapies for other muscle-wasting conditions.

The collaboration with the Medical University of Vienna provides Leksum with access to clinical expertise and a European trial environment. For the university, the partnership offers an opportunity to participate in cutting-edge translational research that addresses a critical care problem with few effective solutions. The involvement of Phoenestra GmbH as a co-signatory indicates a multi-party effort to bring the therapy forward, combining academic, clinical, and industry capabilities.

For patients and clinicians, the prospect of a therapy that preserves diaphragm function during mechanical ventilation could mean shorter ICU stays, reduced complications, and better long-term outcomes. The reduction in weaning time could also alleviate pressure on intensive care units, which often face capacity constraints. As Leksum works toward closing its Series A and launching the preparatory phase, the agreement represents a tangible step toward testing whether LK-ICU can deliver on its preclinical promise. More details are available in the full announcement, and additional information about the company can be found at Leksum.

Blockchain Registration

QR Code for Blockchain Registration